Company Description
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.
The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder.
The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults.
In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics.
Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose.
It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder.
The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
| Country | United States |
| Founded | 1994 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,164 |
| CEO | Mark Crossley |
Contact Details
Address: 10710 Midlothian Turnpike, Suite 125 North Chesterfield, Virginia 23235 United States | |
| Phone | 804 379 1090 |
| Website | indivior.com |
Stock Details
| Ticker Symbol | INDV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625297 |
| ISIN Number | GB00BN4HT335 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mark Crossley | Chief Executive Officer and Executive Director |
| Ryan Preblick | Chief Financial Officer and Executive Director |
| Dr. Christian Heidbreder | Chief Scientific Officer |
| Jason Thompson | Vice President of Investor Relations |
| Cynthia Cetani | Chief Integrity and Compliance Officer |
| Jeffrey W. Burris J.D. | Chief Legal Officer |
| Richard Simkin | Chief Commercial Officer |
| Jon Fogle | Chief Human Resources Officer |
| Hillel West | Chief Manufacturing and Supply Officer |
| Vishal Kalia | SVice President of US Treatment Access, Support Programs and Business Insights and Chief Impact & Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2024 | 6-K | Report of foreign issuer |
| Nov 26, 2024 | 6-K | Report of foreign issuer |
| Nov 22, 2024 | 6-K | Report of foreign issuer |
| Nov 19, 2024 | 6-K | Report of foreign issuer |
| Nov 18, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 15, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |